Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

What is Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?

Bortezomib-cyclophosphamide-dexamethasone, also known as VCd or CyBorD, is a regimen that may be used for the treatment of multiple myeloma. It contains the anticancer agents bortezomib and cyclophosphamide along with dexamethasone, a corticosteroid.

Save up to 80% off your prescriptions!

How do members experience Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?

Top 5 reported purposes & perceived effectiveness

Purpose Patients Evaluations Perceived Effectiveness
Multiple myeloma 454 38

Common side effects

Side effect Patients Percentage
Fatigue 5
Peripheral neuropathy 5
Constant tiredness 2
Numbness 2
Tiredness 2
Bone pain 1

Side effect severity

Side effects as an overall problem
Severity Evaluations Percentage
Severe 9
Moderate 16
Mild 9
None 4

Member evaluations

annswanson

evaluated on Sep 03, 2015

  • Perceived effectiveness for multiple myeloma: Major
  • Side effects: Moderate
Learn more about our community’s experience with Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

What are people saying about Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)?

479

479

members have reported taking Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)

Join the conversation and connect with people who have taken Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD)
Last updated:

Save up to 80% off your prescriptions!

ADVERTISEMENT

ADVERTISEMENT